Create Account | Sign In: Author or Forum

Search Symptoms

Category: Rheumatology | Monthly Briefing

Back to Journal Articles

May 2010 Briefing - Rheumatology

Last Updated: June 01, 2010.

Here are what the editors at HealthDay consider to be the most important developments in Rheumatology for May 2010. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.

FDA: Proton Pump Inhibitors Linked to Fracture Risk

WEDNESDAY, May 26 (HealthDay News) -- The U.S. Food and Drug Administration has alerted consumers and health care providers regarding the potential increased risk of hip, wrist and spine fractures associated with high doses or long-term use of proton-pump inhibitors (PPIs).

FDA's MedWatch Adverse Event Reporting Program
More Information

Many General Internists Leave Field by Mid-Career

FRIDAY, May 14 (HealthDay News) -- Roughly one out of six general internists are leaving internal medicine by mid-career, a substantially higher proportion compared to internal medicine subspecialists, according to survey results published April 29 in the Journal of General Internal Medicine.

Full Text (subscription or payment may be required)

New FDA Program Targets Misleading Drug Advertising

WEDNESDAY, May 12 (HealthDay News) -- The U.S. Food and Drug Administration has announced the launch of a new program to educate health care providers regarding their role in making certain that advertisements and promotions for prescription drugs are truthful and not misleading.
More Information

Previous: May 2010 Briefing - Pulmonology Next: May 2010 Briefing - Surgery

Reader comments on this article are listed below. Review our comments policy.

Submit your opinion: